Third Harmonic Bio Inc. (THRD) News
Filter THRD News Items
THRD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
THRD News Highlights
- THRD's 30 day story count now stands at 4.
- Over the past 9 days, the trend for THRD's stories per day has been choppy and unclear. It has oscillated between 2 and 2.
- BIO, DRUG and WAVE are the most mentioned tickers in articles about THRD.
Latest THRD News From Around the Web
Below are the latest news stories about THIRD HARMONIC BIO INC that investors may wish to consider to help them evaluate THRD as an investment opportunity.
Third Harmonic Bio Inc (THRD) Reports Q3 2023 Financial Results and Continues Progress Towards ...Financial Position Remains Strong with Sufficient Cash Through At Least 2025 |
Third Harmonic Bio Announces Third Quarter 2023 Financial ResultsOn track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the third quarter ended September 30, 2023. “We |
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Third Harmonic Bio Announces Leadership ChangesSAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. In his new role, Dr. Ray will continue support the company’s Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of |
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare ConferenceSAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET. A live audio webcast will be available within the Investors and Media section of the Third Harmonic Bio w |
Third Harmonic Bio Announces Second Quarter 2023 Financial ResultsIntroduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile U.S. Investigational New Drug (IND) application filing and initiation of clinical trials of THB335 planned for the first half of 2024 Strong financial position with cash and cash equivalents totaling $278.1 million as of June 30, 2023 SAN FRANCISCO, Aug. 10, 2023 ( |
Target downgraded, Spotify upgraded: Wall Street's top analyst callsTarget downgraded, Spotify upgraded: Wall Street's top analyst calls |
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile THB001 demonstrated evidence of pharmacodynamic (PD) activity and clinical benefit in discontinued Phase 1b study in chronic inducible urticaria Extensive nonclinical studies of THB001 identified a potential mechanistic basis for observed hepatotoxicity; structural modifications introduced in THB335 believed to address this risk U.S. Inves |
10 Struggling IPOs To Buy For The Long-TermIn this article we present the list of 10 Struggling IPOs To Buy For The Long-Term. Click to skip ahead and see the 5 Struggling IPOs To Buy For The Long-Term. Given the difficult market conditions over the past year, it’s not surprising that several of the most prominent IPOs over the past 12 months, including […] |
We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |